Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis

Elizabeth M. Van Cott, Michael Laposata, M. Elizabeth Hartnett

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The purpose of the present study was to determine whether using an extended panel of laboratory tests increases the detection of a hypercoagulable state in patients with ocular thromboses. Twenty consecutive patients with ocular thromboses (vein, artery, or choriocapillaris occlusions) underwent testing for activated protein C resistance/factor V Leiden, prothrombin G20210A, lupus anticoagulant, anticardiolipin antibodies, hyperhomocysteinemia, and deficiencies of protein C, protein S, and antithrombin. For each patient, we selected two age-matched and gender-matched individuals without ocular thromboses as controls. Sixteen of the 20 patients (80%) had one or more laboratory tests that supported a hypercoagulable condition. Prothrombin G20210A (P < 0.02) and hyperhomocysteinemia (P < 0.0006) were significantly more frequent in ocular thrombosis patients compared with controls. The most common condition was antiphospholipid antibody syndrome, present in 40% of patients (confirmed by repeat testing at least 6 weeks later), but this did not reach statistical significance compared with the controls. No patients with ocular thromboses had hereditary abnormalities of protein S, protein C, or antithrombin. In conclusion, an extended panel of laboratory tests improved the detection of a hypercoagulable state in ocular thromboses. Testing for homocysteine, antiphospholipid antibodies, and the prothrombin G20210A mutation should be considered in patients with ocular thromboses.

Original languageEnglish (US)
Pages (from-to)393-397
Number of pages5
JournalBlood Coagulation and Fibrinolysis
Volume15
Issue number5
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Antiphospholipid Antibodies
Prothrombin
Homocysteine
Thrombosis
Mutation
Genes
Hyperhomocysteinemia
Antithrombins
Protein S
Protein C Deficiency
Activated Protein C Resistance
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Antiphospholipid Syndrome
R Factors
Protein C
Veins
Arteries

Keywords

  • Anticardiolipin antibodies
  • Antiphospholipid antibodies
  • Antithrombin
  • Factor V Leiden
  • Homocysteine
  • Hypercoagulable state
  • Lupus anticoagulant
  • Ocular thrombosis
  • Protein C
  • Protein S
  • Prothrombin G20210A

ASJC Scopus subject areas

  • Hematology

Cite this

Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. / Van Cott, Elizabeth M.; Laposata, Michael; Hartnett, M. Elizabeth.

In: Blood Coagulation and Fibrinolysis, Vol. 15, No. 5, 07.2004, p. 393-397.

Research output: Contribution to journalArticle

@article{c691e495e35b4f37bc13e645381729cf,
title = "Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis",
abstract = "The purpose of the present study was to determine whether using an extended panel of laboratory tests increases the detection of a hypercoagulable state in patients with ocular thromboses. Twenty consecutive patients with ocular thromboses (vein, artery, or choriocapillaris occlusions) underwent testing for activated protein C resistance/factor V Leiden, prothrombin G20210A, lupus anticoagulant, anticardiolipin antibodies, hyperhomocysteinemia, and deficiencies of protein C, protein S, and antithrombin. For each patient, we selected two age-matched and gender-matched individuals without ocular thromboses as controls. Sixteen of the 20 patients (80{\%}) had one or more laboratory tests that supported a hypercoagulable condition. Prothrombin G20210A (P < 0.02) and hyperhomocysteinemia (P < 0.0006) were significantly more frequent in ocular thrombosis patients compared with controls. The most common condition was antiphospholipid antibody syndrome, present in 40{\%} of patients (confirmed by repeat testing at least 6 weeks later), but this did not reach statistical significance compared with the controls. No patients with ocular thromboses had hereditary abnormalities of protein S, protein C, or antithrombin. In conclusion, an extended panel of laboratory tests improved the detection of a hypercoagulable state in ocular thromboses. Testing for homocysteine, antiphospholipid antibodies, and the prothrombin G20210A mutation should be considered in patients with ocular thromboses.",
keywords = "Anticardiolipin antibodies, Antiphospholipid antibodies, Antithrombin, Factor V Leiden, Homocysteine, Hypercoagulable state, Lupus anticoagulant, Ocular thrombosis, Protein C, Protein S, Prothrombin G20210A",
author = "{Van Cott}, {Elizabeth M.} and Michael Laposata and Hartnett, {M. Elizabeth}",
year = "2004",
month = "7",
doi = "10.1097/01.mbc.0000114442.59147.8d",
language = "English (US)",
volume = "15",
pages = "393--397",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis

AU - Van Cott, Elizabeth M.

AU - Laposata, Michael

AU - Hartnett, M. Elizabeth

PY - 2004/7

Y1 - 2004/7

N2 - The purpose of the present study was to determine whether using an extended panel of laboratory tests increases the detection of a hypercoagulable state in patients with ocular thromboses. Twenty consecutive patients with ocular thromboses (vein, artery, or choriocapillaris occlusions) underwent testing for activated protein C resistance/factor V Leiden, prothrombin G20210A, lupus anticoagulant, anticardiolipin antibodies, hyperhomocysteinemia, and deficiencies of protein C, protein S, and antithrombin. For each patient, we selected two age-matched and gender-matched individuals without ocular thromboses as controls. Sixteen of the 20 patients (80%) had one or more laboratory tests that supported a hypercoagulable condition. Prothrombin G20210A (P < 0.02) and hyperhomocysteinemia (P < 0.0006) were significantly more frequent in ocular thrombosis patients compared with controls. The most common condition was antiphospholipid antibody syndrome, present in 40% of patients (confirmed by repeat testing at least 6 weeks later), but this did not reach statistical significance compared with the controls. No patients with ocular thromboses had hereditary abnormalities of protein S, protein C, or antithrombin. In conclusion, an extended panel of laboratory tests improved the detection of a hypercoagulable state in ocular thromboses. Testing for homocysteine, antiphospholipid antibodies, and the prothrombin G20210A mutation should be considered in patients with ocular thromboses.

AB - The purpose of the present study was to determine whether using an extended panel of laboratory tests increases the detection of a hypercoagulable state in patients with ocular thromboses. Twenty consecutive patients with ocular thromboses (vein, artery, or choriocapillaris occlusions) underwent testing for activated protein C resistance/factor V Leiden, prothrombin G20210A, lupus anticoagulant, anticardiolipin antibodies, hyperhomocysteinemia, and deficiencies of protein C, protein S, and antithrombin. For each patient, we selected two age-matched and gender-matched individuals without ocular thromboses as controls. Sixteen of the 20 patients (80%) had one or more laboratory tests that supported a hypercoagulable condition. Prothrombin G20210A (P < 0.02) and hyperhomocysteinemia (P < 0.0006) were significantly more frequent in ocular thrombosis patients compared with controls. The most common condition was antiphospholipid antibody syndrome, present in 40% of patients (confirmed by repeat testing at least 6 weeks later), but this did not reach statistical significance compared with the controls. No patients with ocular thromboses had hereditary abnormalities of protein S, protein C, or antithrombin. In conclusion, an extended panel of laboratory tests improved the detection of a hypercoagulable state in ocular thromboses. Testing for homocysteine, antiphospholipid antibodies, and the prothrombin G20210A mutation should be considered in patients with ocular thromboses.

KW - Anticardiolipin antibodies

KW - Antiphospholipid antibodies

KW - Antithrombin

KW - Factor V Leiden

KW - Homocysteine

KW - Hypercoagulable state

KW - Lupus anticoagulant

KW - Ocular thrombosis

KW - Protein C

KW - Protein S

KW - Prothrombin G20210A

UR - http://www.scopus.com/inward/record.url?scp=3142588859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142588859&partnerID=8YFLogxK

U2 - 10.1097/01.mbc.0000114442.59147.8d

DO - 10.1097/01.mbc.0000114442.59147.8d

M3 - Article

VL - 15

SP - 393

EP - 397

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 5

ER -